Wave Life Sciences (WVE) Financials

$5.94 -0.01 (-0.17%)

Closing price 04:00 PM Eastern

Extended Trading

$6.23 +0.29 (+4.88%)

As of 07:45 PM Eastern

Annual Income Statements for Wave Life Sciences

This table shows Wave Life Sciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Income / (Loss) Attributable to Common Shareholders	-97	-58	-162	-122	-321	-194	-147	-102	-56	-19	-5.23
Consolidated Net Income / (Loss)	-97	-58	-162	-122	-150	-194	-147	-102	-56	-19	-5.23
Net Income / (Loss) Continuing Operations	-97	-58	-162	-122	-321	-194	-147	-102	-56	-19	-5.23
Total Pre-Tax Income	-97	-58	-161	-122	-151	-194	-147	-101	-55	-19	-5.15
Total Operating Income	-110	-68	-163	-127	-153	-208	-160	-102	-56	-19	-5.39
Total Gross Profit	108	113	3.65	41	20	16	14	3.89	1.09	0.15	0.00
Total Revenue	108	113	3.65	41	20	16	14	3.89	1.09	0.15	0.00
Operating Revenue	108	113	3.65	41	20	16	14	3.89	1.09	0.15	0.00
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	219	181	166	168	347	224	174	106	57	19	5.39
Selling, General & Admin Expense	59	51	51	46	43	49	40	27	16	10	3.00
Research & Development Expense	160	130	116	122	131	175	134	79	41	9.06	2.40
Total Other Income / (Expense), net	13	9.81	1.58	4.57	5.25	15	13	1.25	0.54	0.14	0.25
Interest & Investment Income	10	7.93	1.57	0.03	0.57	4.94	3.39	1.58	0.59	0.09	-0.01
Other Income / (Expense), net	3.23	1.88	0.01	4.54	4.68	9.74	9.55	-0.33	-0.05	0.06	0.26
Income Tax Expense	0.00	-0.68	0.68	-0.20	-0.84	0.00	0.07	0.84	0.48	0.04	0.08
Basic Earnings per Share	($0.70)	($0.54)	($2.05)	($2.36)	($3.82)	($5.72)	($5.06)	($3.85)	($2.44)	($1.83)	($1.34)
Weighted Average Basic Shares Outstanding	138.28M	106.10M	78.86M	51.83M	39.23M	33.87M	28.97M	26.51M	22.80M	10.50M	3.91M
Diluted Earnings per Share	($0.70)	($0.54)	($2.05)	($2.36)	($3.82)	($5.72)	($5.06)	($3.85)	($2.44)	($1.83)	($1.34)
Weighted Average Diluted Shares Outstanding	138.28M	106.10M	78.86M	51.83M	39.23M	33.87M	28.97M	26.51M	22.80M	10.50M	3.91M
Weighted Average Basic & Diluted Shares Outstanding	153.49M	122.28M	98.10M	60.84M	39.23M	33.87M	28.97M	26.51M	22.80M	10.50M	3.91M

This table shows Wave Life Sciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-47	29	-62	-33	-32	-16	7.00	-21	-27	-44	-39
Consolidated Net Income / (Loss)	-47	29	-62	-33	-32	-16	7.25	-21	-27	-44	-39
Net Income / (Loss) Continuing Operations	-47	29	-62	-33	-32	-16	7.25	-21	-27	-44	-39
Total Pre-Tax Income	-47	29	-62	-33	-32	-16	6.58	-21	-27	-43	-39
Total Operating Income	-50	23	-64	-35	-34	-19	4.44	-23	-30	-44	-39
Total Gross Profit	9.18	84	-7.68	20	13	29	49	22	13	1.24	0.29
Total Revenue	9.18	84	-7.68	20	13	29	49	22	13	1.24	0.29
Operating Revenue	9.18	84	-7.68	20	13	29	49	22	13	1.24	0.29
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	59	61	56	55	47	48	45	46	43	45	39
Selling, General & Admin Expense	18	16	15	14	14	14	13	12	12	14	12
Research & Development Expense	41	45	41	40	33	34	32	33	31	31	28
Total Other Income / (Expense), net	2.93	6.29	2.14	2.07	2.90	2.43	2.13	2.37	2.88	0.54	-0.11
Interest & Investment Income	2.88	3.74	1.80	2.09	2.54	1.84	1.96	2.25	1.87	0.83	0.60
Other Income / (Expense), net	0.05	2.55	0.34	-0.02	0.37	0.58	0.17	0.12	1.01	-0.29	-0.70
Income Tax Expense	0.00	-	0.00	0.00	0.00	-	-0.68	0.00	0.00	0.68	0.00
Basic Earnings per Share	($0.29)	$0.26	($0.47)	($0.25)	($0.24)	($0.14)	$0.07	($0.20)	($0.27)	($0.39)	($0.42)
Weighted Average Basic Shares Outstanding	162.53M	138.28M	132.56M	129.53M	129.27M	106.10M	106.03M	105.46M	102.06M	78.86M	93.90M
Diluted Earnings per Share	($0.29)	$0.26	($0.47)	($0.25)	($0.24)	($0.14)	$0.07	($0.20)	($0.27)	($0.39)	($0.42)
Weighted Average Diluted Shares Outstanding	162.53M	138.28M	132.56M	129.53M	129.27M	106.10M	106.98M	105.46M	102.06M	78.86M	93.90M
Weighted Average Basic & Diluted Shares Outstanding	154.13M	153.49M	152.52M	124.74M	122.46M	122.28M	99.05M	98.98M	98.37M	98.10M	86.90M

This table details how cash moves in and out of Wave Life Sciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Change in Cash & Equivalents	102	112	-62	-34	37	-28	32	-8.18	-8.38	160	0.61
Net Cash From Operating Activities	-151	-19	-128	-89	-116	-188	-23	-84	-32	-13	-4.43
Net Cash From Continuing Operating Activities	-151	-19	-128	-89	-116	-188	-23	-84	-32	-13	-4.43
Net Income / (Loss) Continuing Operations	-97	-58	-162	-122	-150	-194	-147	-102	-56	-19	-5.23
Consolidated Net Income / (Loss)	-97	-58	-162	-122	-150	-194	-147	-102	-56	-19	-5.23
Depreciation Expense	3.90	5.00	6.57	7.48	8.11	7.59	5.58	2.16	0.78	0.59	0.28
Amortization Expense	4.77	4.21	3.54	2.35	1.87	1.61	-0.79	-0.21	-	-	-
Non-Cash Adjustments To Reconcile Net Income	6.43	4.30	13	16	14	20	17	16	7.10	4.11	0.01
Changes in Operating Assets and Liabilities, net	-69	25	11	7.01	9.65	-23	102	0.42	16	1.97	0.51
Net Cash From Investing Activities	-0.94	-1.12	-1.26	-0.56	-1.34	-3.92	-9.94	-19	-5.56	-2.91	-0.26
Net Cash From Continuing Investing Activities	-0.94	-1.12	-1.26	-0.56	-1.34	-3.92	-9.94	-19	-5.56	-2.91	-0.26
Purchase of Property, Plant & Equipment	-0.94	-1.12	-1.36	-0.56	-1.34	-3.92	-9.94	-19	-5.57	-1.86	-0.59
Purchase of Investments	0.00	0.00	-75	0.00	-	-	-	-	-	-	-
Sale of Property, Plant & Equipment	0.00	0.00	0.11	0.00	-	-	-	-	0.00	-	0.01
Sale and/or Maturity of Investments	0.00	0.00	75	0.00	-	-	-	-	-	-	-
Net Cash From Financing Activities	254	133	67	56	155	164	65	94	29	176	5.62
Net Cash From Continuing Financing Activities	254	133	67	0.86	155	164	65	94	29	176	5.62
Issuance of Debt	202	35	0.00	-	-	-	0.02	0.06	-	0.13	0.00
Issuance of Common Equity	29	94	66	0.61	154	162	60	94	30	113	5.59
Other Financing Activities, net	23	3.59	1.33	0.25	0.74	2.61	5.11	0.93	0.26	0.11	0.03

This table details how cash moves in and out of Wave Life Sciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-59	-8.86	157	-27	-19	60	-33	-36	120	-8.45	-26
Net Cash From Operating Activities	-63	-44	-46	-27	-33	-33	-34	-37	86	-33	-26
Net Cash From Continuing Operating Activities	-63	-44	-46	-27	-33	-33	-34	-37	86	-33	-26
Net Income / (Loss) Continuing Operations	-47	29	-62	-33	-32	-16	7.25	-21	-27	-44	-39
Consolidated Net Income / (Loss)	-47	29	-62	-33	-32	-16	7.25	-21	-27	-44	-39
Depreciation Expense	0.88	0.91	0.95	1.00	1.04	1.08	1.20	1.29	1.43	1.51	1.64
Amortization Expense	1.29	1.25	1.21	1.17	1.14	1.10	1.07	1.03	1.01	0.98	0.96
Non-Cash Adjustments To Reconcile Net Income	4.95	1.48	1.83	1.83	1.30	-3.14	2.28	3.41	1.75	1.94	2.44
Changes in Operating Assets and Liabilities, net	-23	-77	11	1.46	-5.35	-16	-46	-22	109	5.84	8.32
Net Cash From Investing Activities	-0.17	-0.09	-0.38	-0.05	-0.42	-0.36	-0.20	-0.07	-0.49	25	-0.50
Net Cash From Continuing Investing Activities	-0.17	-0.09	-0.38	-0.05	-0.42	-0.36	-0.20	-0.07	-0.49	25	-0.50
Purchase of Property, Plant & Equipment	-0.17	-0.09	-0.38	-0.05	-0.42	-0.36	-0.20	-0.07	-0.49	-0.20	-0.46
Net Cash From Financing Activities	4.16	35	204	0.65	15	94	1.67	1.85	35	0.06	0.02
Net Cash From Continuing Financing Activities	4.16	35	204	0.65	15	94	1.67	1.85	35	0.06	0.02
Issuance of Common Equity	1.70	-0.02	14	-	14	56	38	-	0.43	-0.02	-0.10
Other Financing Activities, net	2.45	7.15	15	0.65	0.12	3.47	-1.73	1.85	0.00	0.07	0.11
Effect of Exchange Rate Changes	0.06	-	-	-	-	-	-	-	-	-	-

This table presents Wave Life Sciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Total Assets	352	275	146	207	279	284	296	182	165	165	2.94
Total Current Assets	320	235	99	163	230	185	202	150	152	161	1.49
Cash & Equivalents	302	200	88	151	184	147	175	143	150	161	1.05
Accounts Receivable	1.42	21	0.00	0.00	30	20	10	1.00	-	-	0.20
Prepaid Expenses	9.54	9.91	7.93	6.58	10	9.63	6.59	6.99	1.48	0.15	0.10
Other Current Assets	7.35	4.02	2.11	5.42	5.11	8.69	11	-	-	-	0.07
Plant, Property, & Equipment, net	10	13	17	22	29	36	40	27	8.61	2.79	1.27
Total Noncurrent Assets	22	26	31	22	20	62	54	4.02	4.21	1.25	0.18
Other Noncurrent Operating Assets	18	23	27	18	16	29	0.11	0.41	0.05	0.00	0.00
Other Noncurrent Nonoperating Assets	3.76	3.70	3.66	3.65	3.65	3.65	3.63	3.61	3.60	1.06	0.00
Total Liabilities & Shareholders' Equity	352	275	146	207	279	284	296	182	165	165	2.94
Total Liabilities	135	227	184	167	189	213	215	34	22	4.06	0.91
Total Current Liabilities	111	186	72	64	121	118	130	18	12	3.82	0.88
Accounts Payable	16	13	17	7.28	14	9.07	13	7.60	4.94	2.81	0.13
Accrued Expenses	21	17	18	15	12	16	15	8.90	4.43	0.95	0.61
Current Deferred Revenue	66	150	32	37	92	90	101	1.34	2.71	0.00	0.15
Other Current Liabilities	7.64	6.71	5.50	4.96	3.71	3.24	1.16	0.34	0.01	-	-
Total Noncurrent Liabilities	24	41	112	102	68	94	85	16	9.92	0.24	0.03
Noncurrent Deferred Revenue	6.10	16	80	77	41	63	73	11	8.99	0.00	-
Other Noncurrent Operating Liabilities	18	25	32	25	26	31	2.14	1.62	0.80	0.16	0.03
Redeemable Noncontrolling Interest	7.87	7.87	7.87	7.87	7.87	7.87	7.87	7.87	7.87	7.87	0.00
Total Equity & Noncontrolling Interests	210	40	-45	32	83	64	73	140	135	153	2.03
Total Preferred & Common Equity	210	40	-45	32	83	64	73	140	135	153	2.03
Total Common Equity	210	40	-45	32	83	64	73	140	135	153	-5.85
Common Stock	1,332	1,065	922	838	766	597	413	332	226	189	9.97
Retained Earnings	-1,122	-1,025	-967	-806	-683	-533	-340	-193	-90	-35	-16
Accumulated Other Comprehensive Income / (Loss)	-0.26	-0.12	-0.03	0.18	0.39	0.27	0.15	0.12	-0.29	0.04	0.06

This table presents Wave Life Sciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	288	359	209	235	200	230	267	182
Total Current Assets	258	325	172	197	159	185	220	131
Cash & Equivalents	243	311	154	181	140	173	208	97
Accounts Receivable	0.00	0.00	1.29	0.00	7.00	-	-	-
Prepaid Expenses	8.06	11	12	11	7.51	9.01	9.23	7.42
Other Current Assets	6.84	3.00	4.68	4.71	4.12	2.72	2.80	2.02
Plant, Property, & Equipment, net	9.57	11	12	12	14	15	16	19
Total Noncurrent Assets	21	23	25	25	28	28	30	31
Other Noncurrent Operating Assets	17	19	21	22	24	25	26	28
Other Noncurrent Nonoperating Assets	3.77	3.75	3.73	3.72	3.68	3.67	4.66	3.65
Total Liabilities & Shareholders' Equity	288	359	209	235	200	230	267	182
Total Liabilities	109	209	204	202	233	274	294	178
Total Current Liabilities	87	171	173	166	100	140	133	64
Accounts Payable	14	13	18	12	13	12	12	16
Accrued Expenses	7.81	15	11	6.62	13	10	7.62	11
Current Deferred Revenue	57	136	137	141	68	111	107	32
Other Current Liabilities	7.88	7.40	7.16	6.94	6.50	6.29	6.08	4.93
Total Noncurrent Liabilities	21	38	31	36	133	134	162	114
Noncurrent Deferred Revenue	5.58	18	9.58	13	105	105	131	80
Other Noncurrent Operating Liabilities	16	20	22	24	27	29	31	34
Redeemable Noncontrolling Interest	7.87	7.87	7.87	7.87	7.87	7.87	7.87	7.87
Total Equity & Noncontrolling Interests	172	142	-3.48	25	-40	-52	-35	-4.52
Total Preferred & Common Equity	172	142	-3.48	25	-40	-52	-35	-4.52
Total Common Equity	172	142	-3.48	25	-40	-52	-35	-4.52
Common Stock	1,341	1,293	1,086	1,082	968	964	960	919
Retained Earnings	-1,169	-1,151	-1,089	-1,056	-1,009	-1,016	-995	-924
Accumulated Other Comprehensive Income / (Loss)	-0.20	-0.16	-0.28	-0.20	-0.18	-0.15	-0.05	-0.12

This table displays calculated financial ratios and metrics derived from Wave Life Sciences' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-4.42%	3,005.10%	-91.09%	104.03%	25.61%	10.89%	270.25%	256.50%	618.42%	0.00%	0.00%
EBITDA Growth	-73.09%	62.70%	-35.47%	18.79%	26.76%	-30.44%	-44.07%	-83.27%	-194.86%	-284.34%	-48.79%
EBIT Growth	-62.09%	59.37%	-32.85%	17.63%	25.12%	-32.41%	-46.00%	-84.19%	-189.83%	-274.87%	-45.12%
NOPAT Growth	-62.37%	58.21%	-28.11%	17.19%	26.37%	-30.59%	-55.80%	-83.76%	-188.73%	-257.77%	-50.92%
Net Income Growth	-68.67%	64.46%	-32.38%	18.45%	22.58%	-32.04%	-43.81%	-83.22%	-189.90%	-267.18%	-57.59%
EPS Growth	-29.63%	73.66%	13.14%	38.22%	33.22%	-13.04%	-31.43%	-57.79%	-33.33%	-36.57%	29.47%
Operating Cash Flow Growth	-677.24%	84.79%	-43.59%	23.27%	38.38%	-723.34%	72.68%	-162.09%	-154.85%	-183.03%	-24.64%
Free Cash Flow Firm Growth	-611.76%	79.27%	-36.05%	18.70%	42.39%	-704.76%	77.95%	-202.38%	-145.00%	-147.32%	0.00%
Invested Capital Growth	43.50%	-21.00%	-13.49%	-16.92%	-23.10%	9.97%	-2,063.29%	140.87%	-1,323.77%	-178.65%	0.00%
Revenue Q/Q Growth	102.02%	32.54%	-12.60%	-15.78%	53.99%	-7.09%	21.21%	26.48%	34.98%	0.00%	0.00%
EBITDA Q/Q Growth	30.68%	30.89%	-50.90%	23.52%	18.06%	-10.18%	-5.16%	-13.43%	-26.39%	0.00%	0.00%
EBIT Q/Q Growth	28.93%	28.03%	-46.22%	22.03%	17.01%	-10.27%	-5.44%	-13.67%	-26.29%	0.00%	0.00%
NOPAT Q/Q Growth	27.39%	26.79%	-4.80%	-4.78%	16.46%	-5.89%	-12.55%	-13.60%	-26.53%	0.00%	0.00%
Net Income Q/Q Growth	31.93%	32.31%	-142.05%	39.57%	15.73%	-10.81%	-5.08%	-13.44%	-26.37%	0.00%	0.00%
EPS Q/Q Growth	36.36%	31.65%	9.29%	-7.76%	24.36%	-6.92%	-3.48%	-8.45%	-16.75%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-7.40%	1.02%	-26.05%	21.51%	20.46%	-17.78%	-78.67%	-12.67%	-26.46%	-76.66%	0.00%
Free Cash Flow Firm Q/Q Growth	-23.94%	-83.71%	-29.43%	26.84%	22.29%	-11.14%	-376.13%	-11.92%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	46.52%	11.17%	-5.75%	-26.98%	6.16%	12.00%	3.75%	18.48%	0.05%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%
EBITDA Margin	-90.96%	-50.23%	-4,181.94%	-274.98%	-690.89%	-1,184.87%	-1,007.24%	-2,588.62%	-5,035.35%	-12,268.42%	0.00%
Operating Margin	-101.94%	-60.01%	-4,459.30%	-310.07%	-763.94%	-1,303.37%	-1,106.72%	-2,630.13%	-5,102.56%	-12,696.05%	0.00%
EBIT Margin	-98.96%	-58.35%	-4,459.11%	-298.99%	-740.61%	-1,242.44%	-1,040.47%	-2,638.63%	-5,107.14%	-12,659.21%	0.00%
Profit (Net Income) Margin	-89.57%	-50.76%	-4,434.72%	-298.42%	-746.68%	-1,211.52%	-1,017.43%	-2,619.57%	-5,097.07%	-12,631.58%	0.00%
Tax Burden Percent	100.00%	98.84%	100.42%	99.83%	99.44%	100.00%	100.05%	100.83%	100.87%	100.23%	101.63%
Interest Burden Percent	90.52%	88.01%	99.03%	99.98%	101.38%	97.51%	97.74%	98.46%	98.94%	99.55%	100.23%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-12,926.89%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-12,919.91%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	12,903.39%	0.00%
Return on Equity (ROE)	-73.24%	-1,118.17%	-10,258.19%	-186.60%	-184.78%	-253.41%	-128.25%	-70.28%	-36.61%	-23.50%	-257.97%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1,944.16%	0.00%	0.00%	-971.36%
Operating Return on Assets (OROA)	-34.18%	-31.39%	-92.09%	-50.38%	-52.78%	-68.45%	-62.78%	-59.26%	-33.78%	-22.86%	0.00%
Return on Assets (ROA)	-30.94%	-27.30%	-91.58%	-50.28%	-53.21%	-66.75%	-61.39%	-58.84%	-33.71%	-22.81%	0.00%
Return on Common Equity (ROCE)	-68.89%	593.60%	40,944.99%	-164.17%	-166.85%	-227.29%	-119.42%	-66.46%	-34.71%	-21.24%	744.12%
Return on Equity Simple (ROE_SIMPLE)	-46.30%	-145.12%	358.88%	-376.16%	-181.10%	-303.83%	-199.94%	-73.05%	-41.27%	-12.51%	-257.97%
Net Operating Profit after Tax (NOPAT)	-77	-48	-114	-89	-107	-146	-112	-72	-39	-14	-3.78
NOPAT Margin	-71.36%	-42.01%	-3,121.51%	-217.05%	-534.76%	-912.36%	-774.71%	-1,841.09%	-3,571.79%	-8,887.24%	0.00%
Net Nonoperating Expense Percent (NNEP)	-7.74%	-6.70%	-38.88%	-19.46%	-25.10%	-29.88%	-22.41%	-20.43%	-10.55%	-6.98%	-277.33%
Return On Investment Capital (ROIC_SIMPLE)	-36.89%	-120.10%	252.61%	-	-	-	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	54.50%	45.27%	1,384.30%	112.55%	211.73%	305.76%	274.10%	692.91%	1,464.65%	6,837.50%	0.00%
R&D to Revenue	147.44%	114.74%	3,175.01%	297.52%	652.21%	1,097.61%	932.62%	2,037.22%	3,737.91%	5,958.55%	0.00%
Operating Expenses to Revenue	201.94%	160.01%	4,559.30%	410.07%	1,727.89%	1,403.37%	1,206.72%	2,730.13%	5,202.56%	12,796.05%	0.00%
Earnings before Interest and Taxes (EBIT)	-107	-66	-163	-122	-149	-199	-150	-103	-56	-19	-5.13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-99	-57	-153	-113	-139	-189	-145	-101	-55	-19	-4.85
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	9.00	12.62	0.00	5.68	4.64	4.31	16.89	6.99	4.55	2.24	0.00
Price to Tangible Book Value (P/TBV)	9.00	12.62	0.00	5.68	4.64	4.31	16.89	6.99	4.55	2.24	0.00
Price to Revenue (P/Rev)	17.42	4.41	166.70	4.51	19.12	17.20	85.93	250.56	562.16	2,261.48	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	188.33	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	14.70	2.72	144.61	1.03	10.32	8.48	74.99	216.78	431.92	1,253.55	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.11	0.02	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.11	0.02	0.00	0.00	0.00
Financial Leverage	-1.92	-28.79	-78.14	-2.61	-2.09	-2.09	-1.37	-1.02	-1.04	-1.00	-0.52
Leverage Ratio	2.37	40.96	112.01	3.71	3.47	3.80	2.09	1.19	1.09	1.03	1.45
Compound Leverage Factor	2.14	36.05	110.93	3.71	3.52	3.70	2.04	1.18	1.07	1.03	1.45
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	10.22%	2.07%	0.14%	0.09%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.01%	0.04%	0.04%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	10.22%	2.05%	0.09%	0.05%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	388.46%
Noncontrolling Interests to Total Capital	3.62%	16.58%	-21.16%	19.50%	8.69%	11.00%	8.70%	5.23%	5.51%	4.88%	0.00%
Common Equity to Total Capital	96.38%	83.42%	121.16%	80.50%	91.31%	89.00%	81.08%	92.71%	94.36%	95.04%	-288.46%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	-0.06	-0.03	0.00	-0.01	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	1.14	1.38	2.73	8.64	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	-0.06	-0.03	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	-0.08	-0.04	-0.01	-0.01	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	1.48	1.94	3.85	11.92	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	-0.08	-0.04	0.00	-0.01	0.00
Altman Z-Score	3.95	-4.07	-10.69	-5.97	-3.42	-3.82	0.52	14.58	15.83	51.28	0.00
Noncontrolling Interest Sharing Ratio	5.95%	153.09%	499.14%	12.02%	9.71%	10.30%	6.89%	5.43%	5.18%	9.64%	388.46%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.89	1.26	1.38	2.53	1.90	1.57	1.56	8.27	12.50	42.27	1.69
Quick Ratio	2.74	1.19	1.24	2.35	1.77	1.41	1.42	7.89	12.36	42.23	1.42
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-145	-20	-99	-72	-89	-155	-19	-87	-29	-12	-4.75
Operating Cash Flow to CapEx	-16,100.85%	-1,742.69%	-10,181.75%	-15,891.61%	-8,668.31%	-4,804.26%	-230.05%	-443.01%	-573.88%	-674.58%	-768.40%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.35	0.54	0.02	0.17	0.07	0.06	0.06	0.02	0.01	0.00	0.00
Accounts Receivable Turnover	9.62	0.00	0.00	0.00	0.80	1.07	2.62	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	9.33	7.46	0.18	1.59	0.61	0.42	0.43	0.22	0.19	0.07	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	37.93	0.00	0.00	0.00	454.50	342.55	139.27	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	37.93	0.00	0.00	0.00	454.50	342.55	139.27	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-88	-157	-129	-114	-97	-79	-88	4.48	-11	-0.77	0.98
Invested Capital Turnover	-0.88	-0.79	-0.03	-0.39	-0.23	-0.19	-0.35	-1.20	-0.19	1.45	0.00
Increase / (Decrease) in Invested Capital	68	-27	-15	-16	-18	8.77	-92	15	-10	-1.75	0.98
Enterprise Value (EV)	1,592	308	528	42	207	136	1,081	844	472	191	0.00
Market Capitalization	1,887	500	608	185	384	275	1,239	975	614	344	0.00
Book Value per Share	$1.37	$0.40	($0.52)	$0.55	$1.70	$1.86	$2.49	$5.02	$5.74	$7.12	($1.49)
Tangible Book Value per Share	$1.37	$0.40	($0.52)	$0.55	$1.70	$1.86	$2.49	$5.02	$5.74	$7.12	($1.49)
Total Capital	217	48	-37	40	91	72	90	151	143	162	2.03
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	9.25	3.11	0.19	0.14	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	9.25	3.09	0.13	0.08	0.00
Net Debt	-302	-200	-88	-151	-184	-147	-166	-139	-150	-161	-1.05
Capital Expenditures (CapEx)	0.94	1.12	1.26	0.56	1.34	3.92	9.94	19	5.56	1.86	0.58
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-93	-151	-61	-52	-75	-80	-103	-10	-10	-3.59	-0.44
Debt-free Net Working Capital (DFNWC)	209	49	27	98	109	67	72	132	140	158	0.61
Net Working Capital (NWC)	209	49	27	98	109	67	72	132	140	158	0.61
Net Nonoperating Expense (NNE)	20	9.92	48	33	43	48	35	30	17	5.69	1.45
Net Nonoperating Obligations (NNO)	-306	-204	-92	-154	-188	-151	-169	-143	-154	-162	-1.05
Total Depreciation and Amortization (D&A)	8.66	9.21	10	9.84	9.98	9.20	4.79	1.95	0.78	0.59	0.28
Debt-free, Cash-free Net Working Capital to Revenue	-85.54%	-133.64%	-1,684.87%	-127.43%	-376.03%	-499.52%	-711.72%	-261.75%	-952.01%	-2,363.16%	0.00%
Debt-free Net Working Capital to Revenue	193.39%	43.19%	740.37%	240.12%	542.92%	421.22%	501.12%	3,398.74%	12,811.08%	103,702.63%	0.00%
Net Working Capital to Revenue	193.39%	43.19%	740.37%	240.12%	542.92%	421.22%	501.12%	3,398.33%	12,805.40%	103,661.84%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.70)	($0.54)	($2.05)	($2.36)	($3.82)	($5.72)	($5.06)	($3.85)	($2.43)	($1.83)	($1.34)
Adjusted Weighted Average Basic Shares Outstanding	138.28M	106.10M	78.86M	60.84M	49.00M	34.54M	34.19M	27.99M	23.54M	21.55M	3.91M
Adjusted Diluted Earnings per Share	($0.70)	($0.54)	($2.05)	($2.36)	($3.82)	($5.72)	($5.06)	($3.85)	($2.43)	($1.83)	($1.34)
Adjusted Weighted Average Diluted Shares Outstanding	138.28M	106.10M	78.86M	60.84M	49.00M	34.54M	34.19M	27.99M	23.54M	21.55M	3.91M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	($2.36)	($3.82)	($5.72)	($5.06)	($3.85)	($2.43)	($1.83)	($1.34)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	153.49M	122.28M	98.10M	60.84M	39.23M	33.87M	28.97M	26.51M	22.80M	10.50M	3.91M
Normalized Net Operating Profit after Tax (NOPAT)	-77	-48	-114	-89	-107	-146	-112	-72	-39	-14	-3.78
Normalized NOPAT Margin	-71.36%	-42.01%	-3,121.51%	-217.05%	-534.76%	-912.36%	-774.71%	-1,841.09%	-3,571.79%	-8,887.24%	0.00%
Pre Tax Income Margin	-89.57%	-51.36%	-4,416.06%	-298.92%	-750.86%	-1,211.52%	-1,016.96%	-2,597.95%	-5,052.93%	-12,602.63%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Wave Life Sciences' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-26.82%	188.23%	-115.60%	-10.92%	-3.02%	2,245.12%	17,168.07%	5,794.93%	638.80%	-29.80%	-99.22%
EBITDA Growth	-49.11%	273.83%	-992.86%	-56.15%	-18.91%	61.51%	118.59%	45.95%	24.02%	-508.80%	-863.77%
EBIT Growth	-45.93%	240.97%	-1,477.64%	-49.93%	-16.45%	58.73%	111.65%	43.61%	22.63%	-678.61%	-535.02%
NOPAT Growth	-44.54%	275.62%	-1,012.78%	-49.09%	-13.78%	57.12%	118.00%	44.33%	20.50%	-20.64%	-411.36%
Net Income Growth	-48.55%	279.95%	-951.90%	-56.00%	-15.15%	62.81%	118.59%	48.90%	27.53%	-185.27%	-526.07%
EPS Growth	-20.83%	285.71%	-771.43%	-25.00%	11.11%	64.10%	116.67%	67.74%	56.45%	35.00%	-250.00%
Operating Cash Flow Growth	-88.56%	-31.32%	-34.89%	26.27%	-139.09%	0.60%	-34.36%	-29.27%	314.49%	-375.47%	9.01%
Free Cash Flow Firm Growth	-6.97%	-420.19%	-194.56%	-200.68%	-200.56%	193.27%	1,001.14%	370.83%	1,150.48%	-72.07%	127.45%
Invested Capital Growth	55.88%	43.50%	6.16%	31.05%	36.63%	-21.00%	-44.05%	-96.75%	-123.39%	-13.49%	-36.28%
Revenue Q/Q Growth	-89.04%	1,191.04%	-138.98%	57.06%	-56.85%	-40.96%	122.63%	70.98%	943.50%	334.74%	-24.00%
EBITDA Q/Q Growth	-271.98%	145.05%	-87.01%	-2.90%	-100.50%	-331.40%	132.71%	21.64%	35.10%	-11.78%	4.93%
EBIT Q/Q Growth	-295.00%	140.13%	-81.57%	-2.70%	-88.36%	-492.20%	119.76%	20.23%	33.24%	-10.74%	4.39%
NOPAT Q/Q Growth	-251.80%	151.33%	-82.63%	-1.56%	-84.44%	-366.80%	129.83%	22.49%	30.48%	-11.99%	7.74%
Net Income Q/Q Growth	-260.25%	147.35%	-87.65%	-4.33%	-94.13%	-324.16%	134.36%	22.99%	37.30%	-12.06%	5.55%
EPS Q/Q Growth	-211.54%	155.32%	-88.00%	-4.17%	-71.43%	-300.00%	135.00%	25.93%	30.77%	7.14%	32.26%
Operating Cash Flow Q/Q Growth	-44.43%	6.09%	-69.21%	17.84%	-0.58%	3.53%	7.52%	-143.56%	355.75%	-30.39%	11.02%
Free Cash Flow Firm Q/Q Growth	-165.75%	18.83%	40.54%	16.59%	-895.46%	-76.03%	-36.70%	-16.69%	837.84%	-383.00%	115.57%
Invested Capital Q/Q Growth	24.06%	46.52%	-7.88%	-0.69%	2.75%	11.17%	20.72%	7.46%	-85.69%	-5.75%	-8.27%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-518.68%	33.04%	0.00%	-166.78%	-254.55%	-54.78%	13.98%	-95.15%	-207.60%	-3,338.01%	-12,982.11%
Operating Margin	-542.82%	27.42%	0.00%	-177.72%	-274.83%	-64.30%	9.03%	-106.18%	-234.24%	-3,515.98%	-13,648.77%
EBIT Margin	-542.27%	30.47%	0.00%	-177.81%	-271.92%	-62.29%	9.38%	-105.65%	-226.45%	-3,539.39%	-13,894.74%
Profit (Net Income) Margin	-510.93%	34.93%	0.00%	-167.19%	-251.70%	-55.95%	14.74%	-95.47%	-211.97%	-3,527.76%	-13,685.61%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	110.30%	100.00%	100.00%	101.58%	100.00%
Interest Burden Percent	94.22%	114.65%	97.17%	94.03%	92.56%	89.81%	142.47%	90.36%	93.60%	98.12%	98.49%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-10.30%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-105.50%	-73.24%	-243.82%	372.56%	-1,920.16%	-1,118.17%	580.83%	5,222.77%	1,592.24%	-10,258.19%	-325.09%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-217.36%	10.52%	0.00%	-89.55%	-122.19%	-33.50%	4.20%	-17.43%	-15.45%	-73.09%	-303.70%
Return on Assets (ROA)	-204.80%	12.06%	0.00%	-84.20%	-113.11%	-30.09%	6.61%	-15.75%	-14.46%	-72.85%	-299.13%
Return on Common Equity (ROCE)	-97.70%	-68.89%	-210.98%	521.28%	2,787.72%	593.60%	893.46%	21,590.55%	2,910.64%	40,944.99%	-200.62%
Return on Equity Simple (ROE_SIMPLE)	-65.38%	0.00%	-100.62%	2,113.46%	-242.88%	0.00%	209.87%	253.72%	436.18%	0.00%	1,479.42%
Net Operating Profit after Tax (NOPAT)	-35	23	-45	-24	-24	-13	4.90	-16	-21	-30	-27
NOPAT Margin	-379.98%	27.42%	0.00%	-124.41%	-192.38%	-45.01%	9.96%	-74.33%	-163.97%	-2,461.19%	-9,554.14%
Net Nonoperating Expense Percent (NNEP)	-5.56%	2.47%	-7.43%	-5.01%	-3.73%	-2.15%	1.75%	-2.83%	-3.78%	-10.72%	-9.30%
Return On Investment Capital (ROIC_SIMPLE)	-20.29%	10.96%	-	-	-	-33.00%	-	-	-	67.63%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	200.08%	19.27%	0.00%	72.60%	108.06%	47.03%	26.68%	55.48%	94.63%	1,107.67%	4,073.33%
R&D to Revenue	442.75%	53.31%	0.00%	205.12%	266.77%	117.27%	64.29%	150.70%	239.61%	2,508.31%	9,675.44%
Operating Expenses to Revenue	642.82%	72.58%	0.00%	277.72%	374.83%	164.30%	90.97%	206.18%	334.24%	3,615.98%	13,748.77%
Earnings before Interest and Taxes (EBIT)	-50	26	-64	-35	-34	-18	4.62	-23	-29	-44	-40
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-48	28	-61	-33	-32	-16	6.88	-21	-27	-41	-37
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	7.22	9.00	7.22	0.00	29.72	12.62	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	7.22	9.00	7.22	0.00	29.72	12.62	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	11.82	17.42	19.08	5.53	6.68	4.41	6.66	9.79	28.65	166.70	75.07
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	9.58	14.70	13.43	4.21	5.15	2.72	5.11	5.28	15.18	144.61	47.74
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	13.82	9.28	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-2.03	-1.92	-3.92	8.52	-62.11	-28.79	9.21	65.73	17.29	-78.14	-6.16
Leverage Ratio	2.46	2.37	4.78	-11.12	78.24	40.96	-13.04	-88.22	-22.85	112.01	9.29
Compound Leverage Factor	2.32	2.71	4.64	-10.46	72.42	36.79	-18.57	-79.72	-21.39	109.90	9.15
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	4.38%	3.62%	5.27%	179.08%	23.67%	16.58%	-24.14%	-17.96%	-29.34%	-21.16%	234.69%
Common Equity to Total Capital	95.62%	96.38%	94.73%	-79.08%	76.33%	83.42%	124.14%	117.96%	129.34%	121.16%	-134.69%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	1.68	5.20	-1.48	-5.54	-3.89	-3.49	-4.74	-5.34	-4.26	-8.01	-6.32
Noncontrolling Interest Sharing Ratio	7.40%	5.95%	13.47%	-39.92%	245.18%	153.09%	-53.83%	-313.39%	-82.80%	499.14%	38.29%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.95	2.89	1.90	0.99	1.19	1.26	1.59	1.32	1.66	1.38	2.05
Quick Ratio	2.78	2.74	1.82	0.90	1.09	1.19	1.47	1.23	1.57	1.24	1.90
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-120	-45	-56	-94	-112	14	59	93	111	-15	5.34
Operating Cash Flow to CapEx	-38,205.45%	-50,753.49%	-12,135.25%	-52,823.08%	-8,017.27%	-9,336.80%	-17,402.53%	-51,745.83%	17,489.16%	-16,392.16%	-5,611.82%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.40	0.35	0.19	0.50	0.45	0.54	0.45	0.16	0.07	0.02	0.02
Accounts Receivable Turnover	0.00	9.62	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	9.55	9.33	4.34	8.26	7.95	7.46	5.29	2.10	0.80	0.18	0.20
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	37.93	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	37.93	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-67	-88	-165	-153	-152	-157	-176	-222	-240	-129	-122
Invested Capital Turnover	-0.96	-0.88	-0.31	-0.59	-0.58	-0.79	-0.57	-0.22	-0.09	-0.03	-0.04
Increase / (Decrease) in Invested Capital	85	68	11	69	88	-27	-54	-109	-133	-15	-33
Enterprise Value (EV)	1,005	1,592	720	465	581	308	437	193	225	528	199
Market Capitalization	1,240	1,887	1,023	611	754	500	569	358	425	608	313
Book Value per Share	$1.12	$1.37	$1.14	($0.03)	$0.21	$0.40	($0.41)	($0.49)	($0.35)	($0.52)	($0.05)
Tangible Book Value per Share	$1.12	$1.37	$1.14	($0.03)	$0.21	$0.40	($0.41)	($0.49)	($0.35)	($0.52)	($0.05)
Total Capital	180	217	150	4.40	33	48	-33	-44	-27	-37	3.36
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-243	-302	-311	-154	-181	-200	-140	-173	-208	-88	-122
Capital Expenditures (CapEx)	0.17	0.09	0.38	0.05	0.42	0.36	0.20	0.07	0.49	0.20	0.46
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-72	-93	-157	-155	-150	-151	-81	-128	-121	-61	-55
Debt-free Net Working Capital (DFNWC)	171	209	154	-1.05	31	49	59	44	87	27	67
Net Working Capital (NWC)	171	209	154	-1.05	31	49	59	44	87	27	67
Net Nonoperating Expense (NNE)	12	-6.29	17	8.43	7.44	3.18	-2.35	4.67	6.21	13	12
Net Nonoperating Obligations (NNO)	-247	-306	-315	-158	-186	-204	-144	-178	-213	-92	-126
Total Depreciation and Amortization (D&A)	2.16	2.16	2.16	2.17	2.18	2.18	2.26	2.32	2.44	2.50	2.60
Debt-free, Cash-free Net Working Capital to Revenue	-69.06%	-85.54%	-293.16%	-140.28%	-132.87%	-133.64%	-95.16%	-351.46%	-812.90%	-1,684.87%	-1,313.13%
Debt-free Net Working Capital to Revenue	162.58%	193.39%	286.86%	-0.95%	27.36%	43.19%	68.54%	121.67%	586.90%	740.37%	1,608.98%
Net Working Capital to Revenue	162.58%	193.39%	286.86%	-0.95%	27.36%	43.19%	68.54%	121.67%	586.90%	740.37%	1,608.98%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.29)	$0.26	($0.47)	($0.25)	($0.24)	($0.14)	$0.07	($0.20)	($0.27)	($0.39)	($0.42)
Adjusted Weighted Average Basic Shares Outstanding	162.53M	138.28M	132.56M	129.53M	129.27M	106.10M	106.03M	105.46M	102.06M	78.86M	93.90M
Adjusted Diluted Earnings per Share	($0.29)	$0.26	($0.47)	($0.25)	($0.24)	($0.14)	$0.07	($0.20)	($0.27)	($0.39)	($0.42)
Adjusted Weighted Average Diluted Shares Outstanding	162.53M	138.28M	132.56M	129.53M	129.27M	106.10M	106.98M	105.46M	102.06M	78.86M	93.90M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	154.13M	153.49M	152.52M	124.74M	122.46M	122.28M	99.05M	98.98M	98.37M	98.10M	86.90M
Normalized Net Operating Profit after Tax (NOPAT)	-35	16	-45	-24	-24	-13	3.11	-16	-21	-30	-27
Normalized NOPAT Margin	-379.98%	19.20%	0.00%	-124.41%	-192.38%	-45.01%	6.32%	-74.33%	-163.97%	-2,461.19%	-9,554.14%
Pre Tax Income Margin	-510.93%	34.93%	0.00%	-167.19%	-251.70%	-55.95%	13.36%	-95.47%	-211.97%	-3,472.80%	-13,685.61%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Wave Life Sciences' Financials

When does Wave Life Sciences's financial year end?

According to the most recent income statement we have on file, Wave Life Sciences' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Wave Life Sciences' net income changed over the last 10 years?

Wave Life Sciences' net income appears to be on an upward trend, with a most recent value of -$97.01 million in 2024, rising from -$5.23 million in 2014. The previous period was -$57.51 million in 2023. Find out what analysts predict for Wave Life Sciences in the coming months.

What is Wave Life Sciences's operating income?

Wave Life Sciences's total operating income in 2024 was -$110.40 million, based on the following breakdown:

Total Gross Profit: $108.30 million
Total Operating Expenses: $218.71 million

How has Wave Life Sciences revenue changed over the last 10 years?

Over the last 10 years, Wave Life Sciences' total revenue changed from $0.00 in 2014 to $108.30 million in 2024, a change of 10,830,200,000.0%.

How much debt does Wave Life Sciences have?

Wave Life Sciences' total liabilities were at $134.82 million at the end of 2024, a 40.7% decrease from 2023, and a 14,698.9% increase since 2014.

How much cash does Wave Life Sciences have?

In the past 10 years, Wave Life Sciences' cash and equivalents has ranged from $1.05 million in 2014 to $302.08 million in 2024, and is currently $302.08 million as of their latest financial filing in 2024.

How has Wave Life Sciences' book value per share changed over the last 10 years?

Over the last 10 years, Wave Life Sciences' book value per share changed from -1.49 in 2014 to 1.37 in 2024, a change of -191.9%.

Related Companies

This page (NASDAQ:WVE) was last updated on 5/27/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Wave Life Sciences (WVE) Financials

Frequently Asked Questions About Wave Life Sciences' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Wave Life Sciences (WVE) Financials

Annual Income Statements for Wave Life Sciences

Quarterly Income Statements for Wave Life Sciences

Annual Cash Flow Statements for Wave Life Sciences

Quarterly Cash Flow Statements for Wave Life Sciences

Annual Balance Sheets for Wave Life Sciences

Quarterly Balance Sheets for Wave Life Sciences

Annual Metrics And Ratios for Wave Life Sciences

Quarterly Metrics And Ratios for Wave Life Sciences

Frequently Asked Questions About Wave Life Sciences' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools